Study Summary
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
Want to learn more about this trial?
Request More InfoInterventions
anti-BCMA CAR-TBIOLOGICAL
Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
VRD-based regimenDRUG
Bortezomib, Lenalidomide and Dexamethasone
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences | Tianjin | China |